e-learning
resources
Amsterdam 2015
Sunday, 27.09.2015
Lung function: effects on method, machine and disease on the measurement
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Postural change in lung capillary blood volume is less in pulmonary hypertension (PH) compared to healthy controls
Patrick Jak (Amsterdam, Netherlands), Jerica Sinkeldam, Ivo Van der Lee, Herman Groepenhoff, Patrick Jak
Source:
International Congress 2015 – Lung function: effects on method, machine and disease on the measurement
Session:
Lung function: effects on method, machine and disease on the measurement
Session type:
Oral Presentation
Number:
303
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Patrick Jak (Amsterdam, Netherlands), Jerica Sinkeldam, Ivo Van der Lee, Herman Groepenhoff, Patrick Jak. Postural change in lung capillary blood volume is less in pulmonary hypertension (PH) compared to healthy controls. Eur Respir J 2015; 46: Suppl. 59, 303
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH)
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
Is the increase in NO lung transfer due to free plasmatic hemoglobin in pulmonary arterial hypertension?
Source: International Congress 2015 – Pulmonary hypertension in lung disease
Year: 2015
Cardiac function in idiopathic pulmonary arterial hypertension patients with a severely reduced diffusion capacity
Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load
Year: 2015
Hemodynamic effects of different vasodilators in patients with type II pulmonary hypertension (PH)
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014
Reduced pulmonary capillary volume (Vc) is responsable for the increased alveolar exhaled nitric oxide (C
A
NO) in patients with progressive systemic sclerosis (PSS) and pulmonary hypertension (PH)
Source: Eur Respir J 2005; 26: Suppl. 49, 561s
Year: 2005
Vasoreactivity to inhaled nitric oxide does not predict long term survival in pulmonary arterial hypertension
Source: International Congress 2016 – Pulmonary hypertension: the clinic I
Year: 2016
Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study
Source: Annual Congress 2013 –Pulmonary circulation: treatment
Year: 2013
Clinical meaning of low DLCO in idiopathic pulmonary arterial hypertension (IPAH) - Prospective single centre study
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
The relationship of systolic pulmonary arterial pressure with pulmonary function test and the fractional exhaled nitric oxide level in Kyrgyz population.
Source: International Congress 2019 – Imaging for prognostication and disease characterisation: 2019 update
Year: 2019
Nitric oxide and oxygen inhalation during exercise in patients with chronic obstructive lung disease (COPD) and secondary pulmonary hypertension (PH)
Source: Eur Respir J 2001; 18: Suppl. 33, 83s
Year: 2001
Physical training and metabolics of nitric oxide in individuals with idiopathic pulmonary arterial hypertension.
Source: International Congress 2019 – Exercise tolerance and its determinants across pathologies
Year: 2019
Endothelial cell mechanics are altered in pulmonary arterial hypertension (PAH)
Source: Annual Congress 2011 - Experimental pulmonary hypertension
Year: 2011
Role of tadalafil in patients with hypoxia / lung disease induced (group 3) pulmonary hypertension
Source: International Congress 2016 – Pulmonary hypertension: the clinic I
Year: 2016
Small airways dysfunction in chronic thromboembolic pulmonary hypertension
Source: International Congress 2015 – Dyspnoea and respiratory muscle mechanics dysfunction in disease
Year: 2015
Analysis of pulmonary endothelial microparticles, haemodynamics and functional class in pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Year: 2015
Comparative analysis of estimated and measured maximal voluntary ventilation in patients with pulmonary hypertension
Source: International Congress 2016 – Respiratory muscles and airways function: from physiology to clinical implications
Year: 2016
Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders
Source: Eur Respir J 2002; 19: 664-671
Year: 2002
Exhaled breath olfactory signature of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Pathways in pulmonary arterial hypertension: the future is here
Source: Eur Respir Rev 2012 21: 321-327
Year: 2012
Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS)
Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept